Tiina Moilanen1, Anna Jokimäki1, Olli Tenhunen1,2, Jussi P Koivunen3. 1. Department of Medical Oncology and Radiotherapy, Oulu University Hospital, University of Oulu, and MRC Oulu, P.B. 22, 90029, Oulu, Finland. 2. Finnish Medicines Agency, Helsinki, Finland. 3. Department of Medical Oncology and Radiotherapy, Oulu University Hospital, University of Oulu, and MRC Oulu, P.B. 22, 90029, Oulu, Finland. jussi.koivunen@ppshp.fi.
Abstract
PURPOSE: Cardiotoxicity is the most important side effect of trastuzumab treatment. Heart function monitoring is recommended during the treatment which has led to growing use of resources. The aim of this retrospective study was to determine the frequency and timing of trastuzumab cardiotoxicity and its risk factors in real-world setting. METHODS: Single institute, retrospective collection of data on HER2+ breast cancer patients (n = 246) was carried out through a pharmacy search for patients who had received trastuzumab in 2006-2014. Clinical and pathological factors, treatment history, EF measurements, cardiac medications, cardiovascular disease history, cardiac symptoms, and survival data were collected from patient records. RESULTS: 32 patients (13%) had EF decline ≥ 10%, eleven (4.5%) had EF decline ≥ 20% within 1 year after trastuzumab initiation, and trastuzumab was discontinued due to suspected cardiotoxicity in six patients (2.4%). 49 patients (19.9%) experienced symptoms related to cardiotoxicity during therapy, which accumulated among those with EF drop. Underlying cardiovascular diseases and multiple (≥ 2) cardiac medications were related to EF drop (≥ 20%) and trastuzumab discontinuation. Majority of EF drops (≥ 10%) and trastuzumab discontinuations were seen within 6months of trastuzumab initiation and recovery of EF drop to < 10% of the baseline was seen in most cases (62.5%). There was no statistically significant difference in the survival of patients according to EF drop. CONCLUSIONS: Trastuzumab cardiotoxicity seems to accumulate among patients with underlying cardiac conditions. EF monitoring could be targeted to risk groups without compromising of the cardiac health or survival of HER2-positive breast cancer patients.
PURPOSE:Cardiotoxicity is the most important side effect of trastuzumab treatment. Heart function monitoring is recommended during the treatment which has led to growing use of resources. The aim of this retrospective study was to determine the frequency and timing of trastuzumab cardiotoxicity and its risk factors in real-world setting. METHODS: Single institute, retrospective collection of data on HER2+ breast cancerpatients (n = 246) was carried out through a pharmacy search for patients who had received trastuzumab in 2006-2014. Clinical and pathological factors, treatment history, EF measurements, cardiac medications, cardiovascular disease history, cardiac symptoms, and survival data were collected from patient records. RESULTS: 32 patients (13%) had EF decline ≥ 10%, eleven (4.5%) had EF decline ≥ 20% within 1 year after trastuzumab initiation, and trastuzumab was discontinued due to suspected cardiotoxicity in six patients (2.4%). 49 patients (19.9%) experienced symptoms related to cardiotoxicity during therapy, which accumulated among those with EF drop. Underlying cardiovascular diseases and multiple (≥ 2) cardiac medications were related to EF drop (≥ 20%) and trastuzumab discontinuation. Majority of EF drops (≥ 10%) and trastuzumab discontinuations were seen within 6months of trastuzumab initiation and recovery of EF drop to < 10% of the baseline was seen in most cases (62.5%). There was no statistically significant difference in the survival of patients according to EF drop. CONCLUSIONS:Trastuzumab cardiotoxicity seems to accumulate among patients with underlying cardiac conditions. EF monitoring could be targeted to risk groups without compromising of the cardiac health or survival of HER2-positive breast cancerpatients.
Entities:
Keywords:
Breast cancer; Cardiotoxicity; HER2 amplification; Trastuzumab
Authors: H J Burstein; I Kuter; S M Campos; R S Gelman; L Tribou; L M Parker; J Manola; J Younger; U Matulonis; C A Bunnell; A H Partridge; P G Richardson; K Clarke; L N Shulman; E P Winer Journal: J Clin Oncol Date: 2001-05-15 Impact factor: 44.544
Authors: Sunil Verma; David Miles; Luca Gianni; Ian E Krop; Manfred Welslau; José Baselga; Mark Pegram; Do-Youn Oh; Véronique Diéras; Ellie Guardino; Liang Fang; Michael W Lu; Steven Olsen; Kim Blackwell Journal: N Engl J Med Date: 2012-10-01 Impact factor: 91.245
Authors: D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich Journal: Science Date: 1989-05-12 Impact factor: 47.728
Authors: Kaitlin B Baron; Jennifer R Brown; Brian L Heiss; Joanne Marshall; Nancy Tait; Katherine H R Tkaczuk; Stephen S Gottlieb Journal: J Card Fail Date: 2014-06-04 Impact factor: 5.712
Authors: Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245
Authors: Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245
Authors: M Khair ElZarrad; Partha Mukhopadhyay; Nishant Mohan; Enkui Hao; Milos Dokmanovic; Dianne S Hirsch; Yi Shen; Pal Pacher; Wen Jin Wu Journal: PLoS One Date: 2013-11-08 Impact factor: 3.240
Authors: Erin J Aiello Bowles; Robert Wellman; Heather Spencer Feigelson; Adedayo A Onitilo; Andrew N Freedman; Thomas Delate; Larry A Allen; Larissa Nekhlyudov; Katrina A B Goddard; Robert L Davis; Laurel A Habel; Marianne Ulcickas Yood; Catherine McCarty; David J Magid; Edward H Wagner Journal: J Natl Cancer Inst Date: 2012-09-05 Impact factor: 13.506
Authors: Slavica Janeva; Toshima Z Parris; Salmir Nasic; Shahin De Lara; Karolina Larsson; Riccardo A Audisio; Roger Olofsson Bagge; Anikó Kovács Journal: BMC Cancer Date: 2021-04-21 Impact factor: 4.430
Authors: Bruno Henrique Rala de Paula; Maria Eduarda Teixeira Ferro Costa; Carlos Augusto Moreira de Sousa; José Bines Journal: World J Cardiol Date: 2022-07-26